Ajinomoto Co., Inc. has agreed to acquire Forge, a manufacturer of genetic medicines, in an all-cash deal for $620 million. Forge is a viral vector and plasmid contract development and manufacturing organization (CDMO) and clinical-stage therapeutics company, enabling access to potentially life-changing gene therapies by bringing them from concept to reality.
Acquisition extends global capabilities in AAV and plasmid gene therapy manufacturing for Ajinomoto, Co. Inc., diversifying and strengthening their current contract development and manufacturing.
CDMO Ajinomoto forges ahead with Forge Biologics in $620M acquisition fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.
Forge Biologics Selected as an AAV Manufacturing Partner for California Institute for Regenerative Medicine to Help Accelerate Gene Therapy Programs tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Forge Biologics and OBiO Technology Sign Separate Gene Therapy Deals genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.